Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7134273 | 0.79 | CA12 (0.47) | ADRA2AADRA1AALDH1A1TSHRMAPK1 | |
| SCHEMBL14328441 | 0.78 | ABCB11 (0.45) | ADRA2AADRA1AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL22852400 | 0.78 | ALDH1A1 (0.47) | ADRA2AADRA1AKDM4EALDH1A1MAPK1 | |
| SCHEMBL7284764 | 0.77 | KDM4E (0.43) | ADRA2AADRA1AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL24517232 | 0.76 | PTGDR2 (0.37) | ALDH1A1HSD17B10MAPK1 | |
| SCHEMBL31394486 | 0.76 | PTGDR2 (0.37) | ALDH1A1HSD17B10MAPK1 | |
| SCHEMBL609936 | 0.74 | ADRA2A (0.41) | ADRA2AADRA1AMAPK1CYP2D6 | |
| SCHEMBL24517236 | 0.73 | — | — | |
| SCHEMBL6408281 | 0.73 | NPC1 (0.44) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL22852537 | 0.72 | ALDH1A1 (0.46) | KDM4EALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171354-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | PFIZER INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030208079-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | PFIZER INC. | 2003-11-06 | — | — | US | disclosed |
| EP-1032571-B1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1032571-A1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999025714-A1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171354-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | HRH2, TACR1, HRH4 | ADRA2A 342/4885ADRA1A 396/4885KDM4E 4042/4885 |
| US-20030208079-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | TACR1, HRH2, GRPR | ADRA2A 328/4885ADRA1A 226/4885KDM4E 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.